anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to compounds, compositions and methods for biofilm disruption and prevention. In particular, the invention relates to pharmaceutical compositions for the disruption of biofilm and prevention of biofilm in patients. The invention also relates to anti-biofouling compositions for the disruption of biofilm and prevention of biofilm on surfaces. The invention also relates to the removal of biological material from surfaces. The compositions of the invention include microbial nucleases, such as theBacilluslicheniformisnucB deoxyribonuclease, or alternatively theBacilluslicheniformisbarnase ribonuclease. Further embodiments provide a nucB deoxyribonuclease and a barnase ribonuclease fromBacilluslicheniformisstrain El-34-6.
A biocompatible polymer hybrid nanocomposite coating on a surface of a substrate, such as titanium and its alloys. The coating can be achieved by an electrostatic spray coating, preferably using ultra-high molecular weight polyethylene (UHMWPE) as a matrix for the coating. For example, up to 2.95 wt. % carbon nanotubes can be used as reinforcement, as can up to 4.95 wt. % hydroxyapatite. A dispersion of CNTs and HA in the coating is substantially uniform. The tribological performance of such coatings include high hardness, improved scratch resistance, excellent wear resistance, and corrosion resistance compared to pure UHMWPE coatings.
Participants from both groups will be asked to complete two follow up neurocognitive assessments face to face at MSKCC. The first will be completed within 1-4 weeks after completing the memory training and the second will take place 3-4 months after completing the memory training. Collateral sources will be contacted at these same points to complete their brief assessments as well to test for maintenance of the treatment effect.
The present invention relates to compounds of formula (IIIa), which are suitable for use as anti-infectives, particularly as antibiotics. X1 is N or CH. …. is a single or a double bond. When …. is a single bond then X2 is selected from the group consisting of CH, N, and N(O), and Y is selected from the group consisting of optionally substituted C3-C10 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted phenyl, and optionally substituted 6-membered heteroaryl. When …. is a double bond then X2 is C, and, and Y is selected from the group consisting of optionally substituted C3-C10 alkylidene, and optionally substituted C3-C8 cycloalkylidene. E is CH, C-OMe or N. Each instance of Z2 is independently selected from CH, CF and N. The invention further relates to the use of such compounds in therapeutic applications, as well as pharmaceutical composition comprising such compounds.
At entry, subjects will switch from continuous HAART to SCT. All subjects will then be followed to assess viral load breakthrough over 48 weeks on SCT.
Myeloproliferative Neoplasms (MPN) are hematological malignancies characterized by an increased risk of thrombosis, in particular in Polycythemia Vera (PV) and Essential Thrombocythemia (ET). Predicting the risk of thrombosis in PV and ET patients helps at determining their care (use of antiaggregant and cytoreductive therapies), but relies only on limited clinical and biological criteria (age over 60 years, history of thrombosis, presence of the JAK2V617F mutation, presence of cardiovascular risk factors). Monocytes sub-populations could represent a new biomarker of thrombotic risk in PV and ET patients. Indeed, it has been shown that monocytes are activated and exhibit pro-thrombotic properties in MPN patients, especially those with a history of thrombosis. Some studies have suggested the CD16+ monocytes (intermediate and non-classical monocytes) are associated with an increased risk of arterial thrombosis. Because these monocytes are observed in inflammatory contexts, and because MPN are associated with a chronic inflammation, MPN could be associated with an increase of the proportion or the absolute count of CD16+ monocytes that could be involved in thrombotic complications observed in PV and ET patients.

In this project, an association between the proportion of CD16+ monocytes and thrombosis in PV and ET patients will be searched. Monocytes sub-populations will be studied in PV and ET patients at diagnosis as described by Selimoglu-Buet et al.1 The proportion of CD16+ (intermediate + non-classical) monocytes will be compared between patients presenting with a history of thrombosis and those without any history of thrombosis. The association between the absolute count and the proportion of CD16+, intermediate and non-classical monocytes and the occurrence of thrombosis before diagnosis, the MPN phenotype, the driver mutation, the allelic burden, the clinico-biological presentation and the existence of an inflammatory state will also be evaluated. Due to the low frequency and the high latency of thrombosis reoccurrence, patients' samples only at diagnosis (or during the year after diagnosis) will be analyzed and an association with a history of thrombosis will be made.
Participants allocated to the vitamin D Group will be given a six-month supply of vitamin D3 supplementation. Participants in the vitamin D Group will receive a bottle of 2,000 International Units (IU) vitamin D3 drops (Ddrops®, Ddrops Company). Participants will be instructed to take two drops daily for six months, for a total daily dose of 4,000 IU.
BCMA+ R/R multiple myeloma patients be treated with a single dose of GC012F cells. Total dose of (1-5)\*10E5/kg cells will be administered at Day 0.
A system for storage and reconstitution of IV solutions is provided. The system may include one or more storage reconstitution devices, each configured to store and manipulate an IV solution container containing a crystalline form of an IV solution, the crystalline form of the IV solution including a hydration chemical and a therapeutic drug. The crystalline hydration chemicals may include crystalline salts and sugars. The container may also be sufficiently dimensionally accurate to be mechanically manipulated and configured such that no sharp object, such as a needle, is required for delivering the fluid to or from the container, for example. Each storage reconstitution device may store a stack of containers and may include an assembly for retrieving the containers from the storage portion and an assembly for reconstituting the contents therein using a sterile water source within the device. IV doses can be manufactured at appropriate standards, which can be reconstituted mechanically to produce high quality doses in real time at a patient care unit or pharmacy.
National trauma center verification relies on a commitment to injury prevention efforts, including prevention of community-level violence. Hospital-Based Violence Recovery Programs (HVIPs) have expanded across the country as extensions of level I and II trauma centers to address trauma recidivism with individual behavioral modification during the "teachable moment." There is little evidence that has demonstrated consistent effectiveness of this approach. One possible reason is the difficulty for community-based violence prevention specialists from HVIP programs to address the larger inequities in the Structural and Social Determinants of Health (SSDOH) that lead to violence through. Medical-Legal Partnership is one approach that has demonstrated evidence and success in improving health outcomes and reducing health-harming legal needs of patients, by connecting legal experts to medical experts for holistic care. This has yet to be done for trauma patients and has, to our knowledge, not been incorporated into any HVIP approach thus far. This clinical trial will evaluate the effectiveness of the HVIP-MLP model to address legal needs rooted in the SSDOH and improve violence-related outcomes. As secondary objectives, it will also evaluate whether the HVIP-MLP model can improve health-related quality of life, PTSD symptoms, and perceived stress among study participants. This novel HVIP-MLP approach has the potential to broadly impact the HVIP model to include an MLP component to all trauma centers for verification to support patients, families and providers alike in this important public health work.
Agents which modulate a bcl family member to control axonal growth and regeneration are described. These bcl modulating agents promote axonal growth and regeneration in the neural cells of a subject. Compositions for promoting axonal cell growth in a subject also are described. The compositions of the present invention include an effective amount of an agent which modulates a bcl family member and in a pharmaceutically acceptable carrier. Other described aspects include packaged drugs for treating a state characterized by diminished potential for axonal growth. The packaged compounds and agents also include instructions for using the agent to promote axonal growth in a subject. An exemplary agent is lithium or a salt thereof.
This R21 provides a multidisciplinary One Health approach to developing and evaluating a novel Cat Assisted Training (CAT) animal assisted intervention (AAI) for early adolescents with developmental disabilities (DD) and their family cat. The novel CAT intervention will be a 6-week cat walking and training program for youth 10 - 12 years old. Participants will learn how to respond appropriately to cat body language, practice fear-free and positive reinforcement-based handling, and training skills, and how to fit a harness and walk their cats on leash. For the human participants, skills and behaviors learned during the intervention are expected to promote and support long-term physical activity, social wellbeing, and lasting feelings of responsibility even after the intervention itself has concluded. We also expect these experiences to improve the relationship between the child participant and household cat, and in turn, reduce cat stress in the child's presence and increase cat sociability and indicators of behavioral wellbeing. Because each child will participate with a cat already living in their household, this program will create a unique active partnership between child and cat that considers the health and wellbeing of both partners. Recent pilot work by PIs Udell \& MacDonald has revealed physical and social-emotional improvements in children with and without developmental disabilities following a pet dog-partner based AAI. Dogs also showed increased sociability and attachment towards their child partner after AAI participation. Work by PI Udell \& Vitale has demonstrated that many cats are highly social and form strong attachment bonds with humans, that cats can be successfully trained a wide range of behaviors, including leash walking, and that cat training classes result in high participant retention rates. Cat social behavior and welfare is also heavily influenced by human behavior and training, making it highly likely that cats would also benefit from this program. There remains a critical need for further empirical evaluation of AAI practices, especially those that target the specific needs of at-risk populations and youth. Further extending the development and evaluation of activity-based AAIs beyond those that include dogs and horses also helps address the critical need to consider and include diverse human participants, creating new equitable opportunities for AAI involvement to those who may have access to cats, but not dogs and horses (due to practical, health, cultural, socio-economic, or other personal reasons).
In sub-Saharan Africa (SSA), a rising burden of noncommunicable diseases (NCDs) coexists with a persistent high burden of human immunodeficiency virus (HIV). Integrating care for chronic conditions is potentially beneficial, but the optimal approach remains unclear. By use of a narrative review of 14 recent case studies from different SSA countries, examples of NCD and HIV healthcare integration were described. Case studies were categorized into three models: integrating NCD care into existing HIV care (n = 8), integrating HIV care into existing NCD care (n = 2), and simultaneous implementation of HIV and NCD services (n = 4). Facilitators include staff and patient education, while barriers encompass the lack of guidelines and inadequate infrastructure. Providers, patients, and policymakers support integrated care but note several challenges. Available health economics data suggest cost-effectiveness in the long run. Concluding, NCD and HIV healthcare integration in SSA was deemed feasible with models of service integration related to the implementation context.
Shortening the vaginal administration time of carboprost methylate, approximately 20 minutes before the surgery. Carboprost methylate was given when patients enter the operation room area.
This is a randomized, double-blinded, placebo-controlled, parallel group clinical trial to evaluate the efficacy of two Transcranial Magnetic Stimulation (TMS) protocols in patients with major depressive disorder (MDD). 70 ambulatory patients with a MDD diagnosis from the Clinic at the Department of Psychiatry and Mental Health at the Universidad Nacional Autónoma de México (UNAM) will be included. All Patients will complete a total of 15 sessions of treatment in any of four groups: A group of patients will be randomly assigned to receive either 5 active TMS sessions or 2 sessions per week. Sham controls will also be randomly assigned to receive either 5 TMS sessions or 2 sessions per week. Afterwards, all participants will receive 2 sessions per month for a 3 month period. Depressive and anxiety symptoms will be evaluated at baseline, and every 5 TMS sessions during the acute treatment phase, and once at the end of a 3-month follow up. In addition, neuropsychological evaluations will be applied at baseline and at the end of the 15 session's treatment. Sessions will be applied with a MAG pro x 100 transcranial magnetic stimulator. Motor threshold will be set. Sessions will be applied over the left DLPFC at 5 Hz, 30 trains, 100%. Categorical variables will be described by percentages and frequencies. Continuous variables will be described by means and standard deviations. Treatment groups will be compared using Student's T test. Cognitive, anxiety and depressive symptom scale scores between treatment groups will be compared using repeated measures ANOVA.
In the event of a smallpox outbreak, or threat of one, mass immunization of all vulnerable individuals would take place. This would include persons with immunodeficiency as seen post Hematopoietic Stem Cell Transplant (HSCT). The current Food and Drug Administration (FDA) approved smallpox vaccine (Dryvax®) is a live replicating virus (vaccinia) and is contraindicated in both immunocompromised persons and those in close physical contact with them. The Modified Vaccinia Ankara (MVA), specifically IMVAMUNE® has been developed as a safer, less reactogenic vaccine against smallpox. Study participants will include 24 male or female participants, from 18 to 60 years of age. This study assesses the safety, reactogenicity and immunogenicity of 2 doses of MVA-BN (IMVAMUNE®) given to persons who have undergone an HSCT more than 2 years prior to study participation. There are 2 arms in the study, each receiving 2 doses 28 days apart of either 1 x 10\^7 or 1 x 10\^8 tissue culture infectious dose 50 (TCID50). Each arm will be comprised of 12 subjects, 10 of whom will receive IMVAMUNE® and 2 of whom will receive placebo under a double blind, randomized allocation. Subjects will be followed for safety and reactogenicity. Clinical assessments will be performed and blood samples will be obtained sequentially for safety and immunogenicity determinations. All subjects will complete a memory aid for 15 days after each vaccination to record oral temperature and note the occurrence of solicited and unsolicited adverse events as well as any medication use. Adverse events will be collected for 56 days after each vaccination. Serious adverse events and concomitant medications will be collected throughout the entire study period. Study staff will assess subjects clinically at days 14 and 28 after each vaccination and on days 42, 56, 84, and 180. Hematology and blood chemistry studies including hemoglobin, white blood cell and platelet counts and kidney and liver function tests will be obtained. Electrocardiogram and Troponin I or T will be obtained prior to first vaccination and on days 14 and 28 after each immunization and at day 180. Clinical laboratory assays will be conducted in the clinical laboratory at both the Brigham and Women's Hospital or the Dana Farber Cancer Institute. The primary objective of this study is to determine the safety and reactogenicity of MVA in persons who have undergone allogeneic HSCT more than 2 years prior to study participation. The secondary objective of this study is to determine the immunogenicity of MVA in persons who have undergone HSCT more than 2 years prior to study participation. Immunogenicity will be determined by humoral immune responses and cell mediated immune responses.
Participants will be randomized to use the Otoband as instructed by clinical coordinator per study protocol. There are 4 power levels, these participants will receive the experimental device.
Metabolic syndrome (MetS) is associated with development of tauopathies that contribute to cognitive decline. Without functional leptin receptors, male obese Zucker rats (OZRs) develop MetS, and they have increased phosphorylated tau (ptau) with impaired cognitive function. In addition to regulating energy balance, leptin enhances activation of the hippocampus, which is essential for spatial learning and memory. Whether spatial learning and memory are always impaired in OZRs or develop with MetS is unknown. We hypothesized that male OZRs develop MetS traits that promote regional increases in ptau and functional deficits associated with those brain regions. In the medulla and cortex, tau-pSer199,202 and tau-pSer396 were comparable in juvenile (7-8 wk old) lean Zucker rats (LZRs) and OZRs but increased in 18- to 19-wk-old OZRs. Elevated tau-pSer396 was concentrated in the dorsal vagal complex of the medulla, and by this age OZRs had hypertension with increased arterial pressure variability. In the hippocampus, tau-pSer199,202 and tau-pSer396 were still comparable in 18- to 19-wk-old OZRs and LZRs but elevated in 28- to 29-wk-old OZRs, with emergence of deficits in Morris water maze performance. Comparable escape latencies observed during acquisition in 18- to 19-wk-old OZRs and LZRs were increased in 28- to 29-wk-old OZRs, with greater use of nonspatial search strategies. Increased ptau developed with changes in the insulin/phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway in the hippocampus and cortex but not medulla, suggesting different underlying mechanisms. These data demonstrate that leptin is not required for spatial learning and memory in male OZRs. Furthermore, early development of MetS-associated autonomic dysfunction by the medulla may be predictive of later hippocampal dysfunction and cognitive impairment.NEW & NOTEWORTHY Male obese Zucker rats (OZRs) lack functional leptin receptors and develop metabolic syndrome (MetS). At 16-19 wk, OZRs are insulin resistant, with increased ptau in dorsal medulla and impaired autonomic regulation of AP. At 28-29 wk OZRs develop increased ptau in hippocampus with deficits in spatial learning and memory. Juvenile OZRs lack elevated ptau and these deficits, demonstrating that leptin is not essential for normal function. Elevated ptau and deficits emerge before the onset of diabetes in insulin-resistant OZRs.
Metabolic syndrome (MetS) is prevalent and significantly impacts global public health, with obesity being a major risk factor for cardiovascular diseases (CVD) and mortality. Traditional metrics like body mass index (BMI) have limitations in assessing obesity-related risks. The weight-adjusted waist circumference index (WWI) has emerged as a novel obesity metric, this study aimed to evaluate the association of WWI with CVD and mortality in MetS patients. This study used data from 12,641 participants with MetS, derived from the National Health and Nutrition Examination Survey (NHANES) conducted from 1999 to 2020. The WWI was calculated, and its association with CVD and mortality was assessed using multivariate logistic and Cox regression models. The study controlled for potential confounders and performed subgroup and sensitivity analyses to validate the robustness of the findings. The predictive performance of WWI was evaluated using the area under the receiver operating characteristic curve (ROC). Kaplan-Meier (KM) curves further were used to evaluate the associations between WWI and mortality of the MetS population. As WWI values escalated, there was a proportional rise in the risk of CVD and mortality in MetS. The fully adjusted continuous model revealed a 32.0% elevated likelihood of CVD development, a 69.5% increased probability of heart failure (HF), a 51.1% heightened risk for CVD mortality, and a 22.8% augmented risk for all-cause mortality with each one-unit increment in WWI. Comparing the highest to the lowest quartile of WWI, the top quartile exhibited a significantly increased risk of CVD (odds ratio [OR] = 1.883; 95% confidence interval [CI]: 1.276-2.633, p-value = 0.001), HF (OR = 2.909; 95% CI: 1.490-5.677, p-value = 0.002), CVD mortality (hazard ratio [HR] = 2.088; 95% CI: 1.279-3.409, p-value = 0.003), and all-cause mortality (HR = 1.394; 95% CI: 1.070-1.816, p-value = 0.014) among individuals with MetS. Sensitivity and subgroup analyses substantiated the consistency and stability of these associations across various demographic groups. The ROC analysis demonstrated that WWI outperforms BMI in predicting adverse outcomes in MetS. The KM curves validated that higher WWI values was correlated with diminished survival rates in MetS population. The WWI served as a significant indicator for assessing the risk of CVD and mortality in the MetS population. This study recommended the regular assessment of WWI in MetS individuals for evaluating their risk of CVD and mortality, potentially enhancing preventive and treatment strategies for this patient population.
People with non-specific low back pain (NSLBP) demonstrate diversified clinical signs and symptoms. It is because the cause of NSLBP is multifaceted. Due to the varied pathophysiology and clinical behavior, the 'one-suit-all' approach of physiotherapy treatment prescription for people with NSLBP is usually less effective in reducing pain and improving daily function.

Research on identifying subgroups of patients with NSLBP who would benefit from physiotherapy interventions could provide clinicians evidence-based guidelines and enhance the cost-effectiveness of health care service. Earlier research showed that people with NSLBP demonstrated a delay in core muscle activation and general wasting of the trunk and core muscle. These pathological changes support the use of core stability training (e.g., Pilates exercise) to manage people with NSLBP. However, effectiveness of core stability training have not been studied extensively in older adults.
Pregnant women in the control group will be subjected to the routine hospital protocol and will not be subjected to any other intervention. In the pregnancy schools of the hospitals, they are verbally told not to wash and wipe their babies before the umbilical cord falls off. After the training, pregnant women will be given a home follow-up form to record the first bath time of their babies after birth, the umbilical cord fall time and the body temperature of their babies (before bathing, immediately after bathing and 10 minutes after bathing) and will be told how to fill it out.